Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen

Medicus Pharma (NASDAQ:MDCX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Friday.

Several other equities research analysts have also issued reports on the stock. D Boral Capital upgraded shares of Medicus Pharma to a “strong-buy” rating in a report on Monday, April 14th. Maxim Group increased their price objective on shares of Medicus Pharma from $10.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Finally, D. Boral Capital restated a “buy” rating and set a $27.00 target price on shares of Medicus Pharma in a research report on Thursday. One investment analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Medicus Pharma presently has an average rating of “Buy” and an average price target of $23.50.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock opened at $3.63 on Friday. The business has a 50 day moving average of $4.53. Medicus Pharma has a one year low of $1.80 and a one year high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). As a group, research analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current year.

Insiders Place Their Bets

In other Medicus Pharma news, major shareholder Velocity Fund Partners, Lp sold 75,000 shares of the business’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $7.72, for a total value of $579,000.00. Following the completion of the sale, the insider now directly owns 3,248,741 shares of the company’s stock, valued at $25,080,280.52. The trade was a 2.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hedge Funds Weigh In On Medicus Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Interchange Capital Partners LLC bought a new stake in shares of Medicus Pharma during the fourth quarter valued at approximately $3,628,000. Armistice Capital LLC purchased a new position in Medicus Pharma during the 1st quarter worth $4,710,000. Finally, Private Advisor Group LLC bought a new stake in Medicus Pharma during the 1st quarter valued at $211,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.